Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and diagnostic findings in COVID-19 patients: an original research from SG Moscati Hospital in Taranto Italy.
Balzanelli M, Distratis P, Catucci O, Amatulli F, Cefalo A, Lazzaro R, Aityan KS, Dalagni G, Nico A, De Michele A, Mazza E, Tampoia M, D'Errico P, Pricolo G, Prudenzano A, D'Ettorre E, Di Stasi C, Morrone LFP, Nguyen KCD, Pham HV, Inchingolo F, Tomassone D, Gargiulo Isacco C. Balzanelli M, et al. Among authors: de michele a. J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):171-183. doi: 10.23812/20-605-A. J Biol Regul Homeost Agents. 2021. PMID: 33491346
An Alternative "Trojan Horse" Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology.
Balzanelli MG, Distratis P, Aityan SK, Amatulli F, Catucci O, Cefalo A, De Michele A, Dipalma G, Inchingolo F, Lazzaro R, Nguyen KCD, Palazzo D, Tampoia M, Pham VH, Santacroce L, Isacco CG. Balzanelli MG, et al. Among authors: de michele a. Endocr Metab Immune Disord Drug Targets. 2022;22(1):1-5. doi: 10.2174/1871530321666210127141945. Endocr Metab Immune Disord Drug Targets. 2022. PMID: 33504318 Review.
Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial.
Kawut SM, Feng R, Ellenberg SS, Zamanian R, Bull T, Chakinala M, Mathai SC, Hemnes A, Lin G, Doyle M, Andrew R, MacLean M, Stasinopoulos I, Austin E, DeMichele A, Shou H, Minhas J, Song N, Moutchia J, Ventetuolo CE. Kawut SM, et al. Am J Respir Crit Care Med. 2024 May 15. doi: 10.1164/rccm.202402-0371OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 38747680
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM. Mayer EL, et al. J Clin Oncol. 2024 Mar 21:JCO2301940. doi: 10.1200/JCO.23.01940. Online ahead of print. J Clin Oncol. 2024. PMID: 38513188
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL; Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels; Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panel. Burstein HJ, et al. J Clin Oncol. 2024 Apr 20;42(12):1450-1453. doi: 10.1200/JCO.24.00248. Epub 2024 Mar 13. J Clin Oncol. 2024. PMID: 38478799
Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Magbanua MJM, et al. Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-23-2928. Online ahead of print. Clin Cancer Res. 2024. PMID: 38470545
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Smith KL, et al. Cancer. 2024 May 15;130(10):1747-1757. doi: 10.1002/cncr.35187. Epub 2024 Jan 18. Cancer. 2024. PMID: 38236702
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI. Kyalwazi B, et al. JAMA Netw Open. 2023 Dec 1;6(12):e2349646. doi: 10.1001/jamanetworkopen.2023.49646. JAMA Netw Open. 2023. PMID: 38153734 Free PMC article.
263 results